SCHEMBL801639

SCHEMBL801639

Cc1ccccc1-c1cc(C)c(C)c(Nc2n[nH]c3ccc(F)cc23)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 4/20 0.50
GSK3B P49841 4/20 0.50
FADS1 O60427 4/20 0.46
EGFR P00533 1/20 0.39
RIPK2 O43353 4/20 0.39
ITK Q08881 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
GAK O14976 1/20 0.37
LCK P06239 1/20 0.37
TGFBR1 P36897 1/20 0.37
KCNH2 Q12809 1/20 0.37
MAPK14 Q16539 1/20 0.37
RIPK3 Q9Y572 1/20 0.37
MAPT P10636 1/20 0.35
NTRK1 P04629 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801674 0.90 GSK3A (0.62) GSK3AGSK3BFADS1EGFRRIPK2
SCHEMBL805526 0.89 GSK3A (0.46) GSK3AGSK3BFADS1EGFRRIPK2
SCHEMBL802674 0.87 GSK3A (0.44) GSK3AGSK3BFADS1EGFRCYP1A2
SCHEMBL802250 0.85 FADS1 (0.45) GSK3AGSK3BFADS1EGFRRIPK2
SCHEMBL801665 0.83 FADS1 (0.51) GSK3AGSK3BFADS1RIPK2ITK
SCHEMBL802675 0.83 GSK3A (0.51) GSK3AGSK3BFADS1EGFRRIPK2
SCHEMBL802031 0.83 GSK3A (0.45) GSK3AGSK3BFADS1EGFRRIPK2
SCHEMBL801635 0.82 FADS1 (0.49) GSK3AGSK3BFADS1EGFRRIPK2
SCHEMBL801647 0.81 GSK3A (0.48) GSK3AGSK3BFADS1EGFRRIPK2
SCHEMBL13938155 0.79 CYP1A2 (0.54) GSK3AGSK3BFADS1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 GSK3A 2/4885GSK3B 1/4885FADS1 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.